-
Product Insights
Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) – Drugs In Development, 2023
Global Markets Direct’s, ‘Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) - Drugs In Development, 2023’, provides an overview of the Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Mild Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Mild Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Mild Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Progressive Supranuclear Palsy – Drugs In Development, 2023
Global Markets Direct’s, ‘Progressive Supranuclear Palsy - Drugs In Development, 2023’, provides an overview of the Progressive Supranuclear Palsy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally,...
-
Product Insights
Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Hydromethylthionine mesylate in Mild Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Hydromethylthionine mesylate in Mild Cognitive Impairment report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hydromethylthionine mesylate in Mild Cognitive Impairment Drug Details: Hydromethylthionine...
-
Sector Analysis
Alzheimer’s Disease Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030
Alzheimer’s Disease Market Report Overview Alzheimer’s Disease and MCI market size across the 8MM was valued at $2.2 billion in 2020 and is expected to achieve a CAGR of more than 19% during 2020-2030. AD is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. Mild cognitive impairment (MCI) is a phase of the AD continuum in which a gradually progressive cognitive decline occurs and may even become clinically relevant. Alzheimer’s Disease Market Outlook,...
-
Product Insights
Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications. The Progressive Supranuclear Palsy pipeline drugs market research report provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy, complete with analysis by...
-
Track & Monitor
Biosimilars in Pharmaceuticals: Neuro-degenerative receptor binding drug compositions
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Neuro-degenerative receptor binding drug compositions segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...
-
Product Insights
Alzheimer Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
Alzheimer is a progressive neurologic disorder beginning with mild memory loss. It could possibly lead to a loss of the ability to carry on a conversation and respond to the environment. The Alzheimer pipeline market research report provides comprehensive information about the Alzheimer pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – hydromethylthionine mesylate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry hydromethylthionine mesylate Drug Details Hydromethylthionine mesylate (LMTX) is under development for the treatment of...